Government Buys 1.5 Million More Doses of Novavax’s COVID Vaccine
Biotechnology company Novavax announced that it has made a modification to an existing contract with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD) to provide up to 1.5 million more doses of its Nuvaxovid COVID-19 vaccine (also known as “NVX-CoV2373” and “Covovax”), in addition to the 3.2 million […]
Health Care System Mandates COVID Shot, Withdraws Religious and Medical Exemptions
Froedtert Health, a health care system headquartered in Wauwatosa, Wisconsin, is withdrawing religious and medical exemptions held by employees who had originally refused to get the messenger RNA (mRNA) COVID-19 shots. The company informed its employees that they must now get vaccinated with the recently approved Novavax’s COVID vaccine NVX-CoV2373 (also known as “Nuvaxovid” and […]
FDA Grants EUA for Novavax’s COVID Vaccine
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
FDA Panel Recommends EUA for Novavax COVID-19 Vaccine
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]
Novavax’s Protein COVID-19 Vaccine Now Available in Europe
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
